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Abstract
Background Lymph node status is the most important
predictive factor in colorectal carcinoma. Recurrences occur
in 20% of the patients without lymph node metastases. The
sentinel lymph node (SLN) biopsy is a tool to facilitate
identification of micrometastatic disease and aberrant
lymphatic drainage. We studied the feasibility of in vivo
SLN detection in a multi-centre setting and evaluated nodal
micro-staging using immunohistochemistry (IHC).
Materials and methods Sub-serosal injection with Patent
Blue dye was used in the SLN procedure in 69 patients
operated for localized colon cancer in six Dutch hospitals.
Each SLN was examined with routine haematoxylin–eosin
staining. In tumour-negative SLNs, we performed CK7/8 or
18 IHC.
Results The procedure was successful in 67 of 69 patients
(97%). The SLN was negative in 43 patients. In three cases,
it was false negative, resulting in a negative predictive
value of 93% and an accuracy of 96%. In 24 of 27 patients
with lymph node metastases in a successful SLN procedure,
the SLN was positive (sensitivity 89%). In 15 patients, the
SLN was the only positive node (21%). In nine patients, we
only found micrometastases or isolated tumour cells,
resulting in 18% upstaging. Aberrant lymphatic drainage
was seen in three patients (4%).
Conclusion The SLN procedure in localized colon carci-
noma is reliable in a multi-centre setting. It is helpful to
identify patients who would be classified as stage II with
conventional staging (18%) and who might benefit from
adjuvant treatment.
Keywords Coloncarcinoma.Sentinellymphnode.
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Introduction
Survival in patients with colon carcinoma is strongly
correlated with lymph node status: the 5-year disease-free
survival rate is 70–80% for patients with lymph node-
negative disease (stage I/II) but only 45–50% for those with
node-positive disease (stage III) [1]. The presence of lymph
node metastases indicates the use of adjuvant chemotherapy
in these patients, which increases the 5-year survival rate
with about 10% [2]. Despite the favourable prognosis of
patients with localized colon carcinoma without regional
Int J Colorectal Dis (2007) 22:1509–1514
DOI 10.1007/s00384-007-0351-6
Both authors Wendy Kelder and Andries E. Braat contributed equally
to this study.
W. Kelder:P. C. Baas
Department of Surgery, Martini Hospital,
Groningen, The Netherlands
W. Kelder:J. T. M. Plukker (*)
Department of Surgery, University Medical Centre Groningen,
Hanzeplein 1, 9700 RB,
Groningen, The Netherlands
e-mail: j.t.m.plukker@chir.umcg.nl
A. E. Braat: J. E. De Vries: J. W. A. Oosterhuis
Department of Surgery, Isala Klinieken,
Zwolle, The Netherlands
A. Karrenbeld
Department of Pathology, University Medical Centre,
Groningen, The Netherlands
J. A. K. Grond
Department of Pathology, Laboratory of Public Health,
Leeuwarden, The Netherlands
A. E. Braat
Department of Surgery, Leiden University Medical Centre,
Leiden, The Netherlandslymph node metastasis, 20–30% of these patients will
develop recurrent disease after apparently curative resection
[3]. It is possible that in this group of patients, small lymph
node metastases have been missed, resulting in under-
staging. This may be due to an inadequate surgical
lymphadenectomy or insufficient pathological examination
[4]. According to international guidelines, meticulous
pathological examination of at least 12 lymph nodes is
warranted for adequate staging of patients with colon
carcinoma [5]. However, several studies showed that the
minimal number of lymph nodes necessary for correct
staging varied considerably from 6 to 18 to as many as
possible in the study of Goldstein et al. [4, 6–9]. In
addition, in-depth pathological examination of lymph nodes
by immunohistochemical staining for cytokeratin or reverse
transcriptase polymerase chain reaction (RT-PCR) may
reveal micrometastases that could have been missed by
routine haematoxylin and eosin (H&E) examination. Sev-
eral authors have reported a decreased survival rate when
micrometastases are detected in colon carcinoma [10–13].
The possible benefit of adjuvant therapy in this group of
patients is not clear yet.
These (ultra-)staging techniques are time consuming,
labour intensive and costly. For optimal staging, in depth
examination of only the sentinel lymph node (SLN) could
be helpful. In colon carcinoma, the SLNs are defined as the
first one to four blue-stained nodes with the most direct
lymph drainage from the primary tumour. They have the
greatest potential to harbour metastatic disease when
present, enabling focussed examination with multi-level
micro-sectioning of the SLNs to provide a more efficient
and cost-effective detection of micrometastases. In addition,
patterns of aberrant lymphatic drainage can be visualized
with SLN mapping, which may lead to a more extended
resection. Several studies have reported varying results of
the SLN procedure in colon carcinoma [14–20]. This study
presents the results of the SLN procedure in six Dutch
hospitals. The primary aim of this study is to test the
accuracy and sensitivity of the SLN procedure in a multi-
centre setting. Furthermore, we looked at upstaging and
possible aberrant lymphatic drainage.
Materials and methods
This study was performed between May 2002 and May
2005 in five teaching hospitals and one university hospital.
All procedures were supervised by one of the coordinating
surgeons (Plukker, Braat). Only patients with histologically
proven primary colon carcinoma were included in the
study. Patients with distant metastases or gross lymph node
involvement as shown by pre-operative examinations or
palpation during surgery were excluded. The procedure was
only performed when one of the study coordinators was
available for supervision (Plukker, Braat, Kelder). The
study was approved by the local scientific ethics committee,
and all patients had given informed consent. Patients with
rectal cancer were excluded from the study.
SLN mapping was carried out through an open proce-
dure by injection of 1–3 ml Patent Blue with a tuberculin
syringe and 29-gauge needle sub-serosally in four quad-
rants around the tumour. The sub-serosal injection was
carried out before vascular ligation. Within 5 to 10 min
after the blue dye injection, the SLN could be identified by
following the blue-stained lymphatic vessels leading to the
blue-stained SLN. These lymph nodes were tagged with a
long suture. SLNs were defined as the first one to four blue-
stained lymph nodes seen within the regional basin. After
marking of the SLNs, routine resection was performed. If
the SLN was found outside the normal lymphatic basin, we
performed an extended resection. The tumour and all lymph
nodes were examined according to standard guidelines [5].
If the SLNs were negative after routine H&E staining, they
were sectioned at 150-μm intervals and examined at three
levels with H&E as well as immunohistochemistry on
cytokeratins (CK7/8 or 18). Metastases between 0.2 and
2 mm were referred to as micrometastases. Metastases
smaller than 0.2 mm were referred to as isolated tumour cells
[5]. Upstaging was defined as the presence of micrometa-
stases or isolated tumour cells after immunohistochemistry
(IHC) in patients with a negative lymph node status after
H&E.
Definitions
See Fig. 1. Identification rate is the number of patients with
one or more SLNs identified (b)/the total number of
procedures (a)×100%. Negative SLNs were false negative
if one of the other regional lymph nodes (non-SLNs) were
tumour positive (d). The accuracy of the SLN procedure
suggests a conformity of the SLN status and the regional
nodal status, i.e. the total number of patients with a positive
SLN (c)+the number of patients with a true-negative SLN
(e)/the number ofpatients withanidentifiedSLN (b)×100%.
Sensitivity is the number of patients with a positive SLN (c)/
The total number of node positive patients (c+d)×100%.
Upstaging is the number of patients with positive SLNs by
IHC (g)/the number of patients who were node negative by
H&E examination (e+g)×100%.
Results
The SLN procedure was performed in 69 patients. Tumour
characteristics are shown in Table 1. Figure 1 shows the
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examination, a mean of 11 nodes per specimen was found;
per hospital, this varied between 9 and 17 (9, 10, 12, 14, 17,
17, respectively). The mean number of SLNs was 2.3 per
patient. The SLN was identified in 67 out of 69 patients
(97%). One of the two failed procedures was in a patient
with a carcinoma in the sigmoid colon surrounded by a
concurrent diverticulitis. The other patient had extended
lymph node metastases with angio-invasion at pathological
examination. In 28 patients, lymph node metastases were
identified at the pathological examination; this includes the
one case where the SLN procedure failed because of
extensive lymph node metastases (28 of 69, 41%). This
one case with lymph node metastases and a failed
procedure was excluded from further statistical analysis
on the SLN procedure, leaving 27 node-positive patients in
the final analysis. In 24 patients, the SLN was positive,
either with H&E staining or with IHC, resulting in a
sensitivity of 89% (24 of 27) in the group of 67 patients
with a successful SLN procedure. If we leave out the
patients who had a positive sentinel node only after IHC,
the sensitivity is 15 of 18 (83%). In 15 of 24 SLN-positive
patients, the SLN was the only involved lymph node (63%).
In 9 of 27 lymph node-positive patients, metastases were
found only after IHC. In four patients, these were micro-
metastases, whereas in five cases, isolated tumour cells
were found. Therefore, without IHC, the number of node-
positive cases would have been 27 minus 9, which is 18.
This corresponds to a total of 49 node-negative cases by
H&E in the group with a successful SLN procedure. With
IHC, the upstaging is 9 of 49 or 18%. The SLN was
negative in 43 patients. In 40 patients, the non-SLNs were
also negative. This results in a negative predictive value of
93% (40 of 43). One of the three patients with a false-
negative SLN had lymph node metastases with extra-nodal
growth in the non-SLN. In another patient, a small tumour
deposit was found in the mesocolon right next to the
primary tumour. This was classified as N1 according to the
American Joint Committee on Cancer classification, al-
though it is unclear whether this is a true lymph node
metastasis or some kind of ‘in transit’ metastasis. The last
patient with a positive non-SLN showed micrometastases at
H&E examination in a small peritumoural lymph node.
Aberrant lymphatic drainage was seen in three patients
(4%). In two cases, the SLN was found on the left side of
the middle colic artery in patients with a tumour in the
ascending colon. In both cases, an extended right hemi-
Table 1 Tumour characteristics
Characteristics Values
Tumour location
Right colon 35
Left colon 2
Sigmoid colon 32
T-stage
11
21 4
34 8
46
Mean number of lymph nodes 11
Mean number of SLN 2.3
Total nr of pts (69) a
Nr of pts with no SLN
identified (2)
Nr of pts with SLN
identified (67) b
Nr of pts with positive
SLN, H&E / IHC(24)
c
Nr of pts with
negative SLN (43)
Nr of pts with positive
non-SLN (3) d
Nr of pts  with
negative non-SLN
(40) e
Nr of pts with positive
SLN, H&E / IHC(24)
c
Nr of pts with positive 
SLN, H&E / IHC(24)
c
Nr of pts with positive
non-SLN, H&E (9)
Nr of pts with negative
non-SLN, H&E (15)f
Nr of pts with positive
SLN, H&E (15)
Nr of pts with positive
SLN, IHC only (9) g
Fig. 1 Flowchart. SLN Sentinel lymph node, pts patients
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near the rectosigmoid junction with a high para-aortal SLN.
Therefore, we performed an extended left sided resection
en-bloc with a partial para-aortal dissection. None of these
lymph nodes contained metastases. All other SLNs were
found in the mesocolon in close proximity to the tumour. In
these cases, the central lymph node as identified by the
pathologist was always a non-SLN. The accuracy of the
SLN procedure in this study was 96%, as the pathological
status of the SLN corresponds with the definitive lymph
node status in 64 of the 67 patients.
Discussion
With an identification rate of 97%, accuracy of 96%,
sensitivity of 89% and negative predictive value of 93%,
this study shows that it is possible to perform the SLN
procedure properly in patients with localized colon carci-
noma in a multi-centre setting. Other multi-centre studies
showed varying results of this technique (Table 2)[ 14–21].
Our results correlate with those from other larger studies,
which show accuracy and sensitivity rates of 95–98 and
89–93%, respectively [15, 18–20]. Most smaller studies
show worse results with low accuracy and success rates and
corresponding low sensitivity rates and negative predictive
values [14, 17, 21]. In one study, the time between injection
of the blue dye and identifying the SLN was too long,
leading to a larger number of SLNs [17]. It is very likely
that not all of these blue nodes were true SLNs. In the study
by Bertagnolli et al. [14], 79 patients were operated on by
25 different surgeons in 13 different hospitals. A mean of
three procedures per surgeon seems insufficient to ade-
quately learn this technique. It is known that the learning
curve of the SLN in colon carcinoma stabilizes after about
five procedures [20]. To minimize technical failures, the
procedure in our study was performed by a few surgeons
under direct supervision of one of the two surgeons
coordinating this study (Braat, Plukker). Apart from too
few procedures, the worse results in some studies might be
explained by inclusion of patients with advanced disease.
Some studies included patients with clinically apparent
stage III or stage IV disease [21]. Widespread lymph node
metastases could result in obstruction of lymphatic
channels, and lymphatic drainage is bypassed to other
(non-sentinel) lymph nodes. This phenomenon is called
skip-metastasis. It was noted in one of the patients with a
false-negative SLN in our study who had advanced
lymphatic metastases with extra-nodal growth. Patient
selection is therefore important for a reliable SLN
procedure in colon carcinoma. In fact, the SLN procedure
is not useful in patients with clinically apparent stage III
or stage IV disease as false-negativity rates will be higher.
Moreover, in these patients, metastases will be easily
found at routine pathological examination, and the SLN
procedure will not have any additional value. The SLN
procedure could be useful in those patients with (micro)
metastases that would not be identified with routine
pathological examination. Furthermore, the failed proce-
dure in one of our patients with concurrent diverticulitis
also suggests the importance of an undisturbed lymphatic
drainage for a successful SLN procedure.
We saw aberrant lymphatic drainage in three patients
(4%). This percentage correlates with the literature [15, 18,
20]. In this study, none of these aberrant SLNs showed
metastases. However, potentially, these aberrant SLNs are
the only lymph nodes containing metastasis, as shown in a
previous study [22]. In an experimental situation, it seems
justified to perform an extended resection in these cases.
Further study should be performed to justify an extended
resection in the daily practice.
Literature not clearly indicates how many nodes should
be examined to accurately predict lymph node status [6–8,
23, 24]. One study showed that a colon specimen usually
contains about 50 lymph nodes and that more than 70% of
the lymph nodes containing metastases are smaller than
5m m[ 9]. It is also known that the prognosis in node-
negative patients with colon carcinoma is better when more
lymph nodes have been examined [24]. Taking this into
account, the pathologist takes only a sample of the
lymphatic basin of a resected colon specimen, even when
international guidelines are followed, which state that at
least 12 lymph nodes are needed for adequate staging [5].
The mean number of 11 lymph nodes in our study is not
enough to predict lymph node status according to the
international guideline. This fact could theoretically lower
Table 2 Results of multi-centre studies of the SLN procedure in colon cancer
Study Number of patients Number of centres Identification rate (%) Accuracy
(%)
Sensitivity
(%)
Upstaging
(%)
Bilchik et al. [15] 40 3 100 100 100 10
Saha et al. [18] 131 3 99 97 92 16
Bertagnolli et al. [14]7 2 1 3 9 2 8 1 4 2 0
Read et al. [21] 38 2 79 76 25 3
Kelder and Braat 69 6 97 96 89 13 or 18
1512 Int J Colorectal Dis (2007) 22:1509–1514the chance to detect metastases in non-SLN and thus could
lower the false-negative rate. However, we did not find any
differences in false negative rates between the two hospitals
with a mean number of nine and ten examined nodes (40
cases) and the hospitals with more than 12 examined nodes
(29 cases). With regards to upstaging, most studies show an
upstaging of 10–16% [15, 18–20]. However, they calculat-
ed upstaging by dividing the number of IHC-positive
patients by the total number of patients (Fig. 1g/a, 9 of
69, 13% in our group). We think it is better to consider
upstaging solely in the H&E node-negative group, as this is
the group to be upstaged by IHC. Using this method, we
find 18% upstaging in our series. In addition to this true
upstaging, patients with a SLN as the only site of
metastases could have been ‘possibly upstaged,’ as con-
ventional pathological dissection of the mesentery might
have missed this lymph node. The SLN procedure with
patent blue might be able to improve adequacy of the
lymph node examination by selecting the right lymph
nodes, even small nodes less than 5mm, to be examined in
depth by the pathologist. We found the SLN to be the single
lymph node with metastasis in 15 (21%) of the patients
(Fig. 1 f).‘Possible upstaging’ might play a role here, but
we cannot prove this.
As we believe that even isolated tumour cells are
important for staging, we assigned patients with micro-
metastases or isolated tumour cells to the group of node-
positive patients. It must be remarked, however, that these
cases were also used for the calculation of upstaging. Our
idea of the biological importance of micrometastases and
isolated tumour cells is based on a recent meta-analysis that
showed that micrometastases detected retrospectively by
RT-PCR correlated better with overall survival than IHC
and carried significant prognostic value [12].
Regarding the detection of micrometastases, two stud-
ies showed a high reliability of the SLN concept to predict
micrometastases and/or isolated tumour cells also in non-
SLNs. Therefore, it seems sufficient to perform IHC only
on the SLN, while examining the non-SLNs with H&E
[25, 26]. Prospective studies are needed to evaluate the
potential benefit of systemic chemotherapy in patients
with these micrometastases. A reliable SLN procedure
might facilitate this intensive pathological examination by
allowing focussed examination of only the SLN and
thereby aid in a better patient selection for adjuvant
t h e r a p yi nt h ef u t u r e .
References
1. Hermanek P (1995) pTNM and residual tumor classifications:
problems of assessment and prognostic significance. World J Surg
19:184–190
2. Hermanek P (1995) Efficacy of adjuvant fluorouracil and folinic
acid in colon cancer. International Multicentre Pooled Analysis of
Colon Cancer Trials (IMPACT) investigators. Lancet 345:939–
944
3. Wolmark N, Fisher B, Wieand HS (1986) The prognostic value of
the modifications of the Dukes’ C class of colorectal cancer. An
analysis of the NSABP clinical trials. Ann Surg 203:115–122
4. Joseph NE, Sigurdson ER, Hanlon AL, Wang H, Mayer RJ,
MacDonald JS, Catalano PJ, Haller DG (2003) Accuracy of
determining nodal negativity in colorectal cancer on the basis of
the number of nodes retrieved on resection. Ann Surg Oncol
10:213–218
5. Greene FL, Page DL, Fleming ID et al (2002) American Joint
Committee on Cancer—cancer staging handbook, TNM classifi-
cation of malignant tumors, 129. Springer, New York, NY
6. Fielding LP, Arsenault PA, Chapuis PH, Dent O, Gathright B,
Hardcastle JD, Hermanek P, Jass JR, Newland RC (1991)
Clinicopathological staging for colorectal cancer: an International
Documentation System (IDS) and an International Comprehensive
Anatomical Terminology (ICAT). J Gastroenterol Hepatol 6:325–
344
7. Goldstein NS (2002) Lymph node recoveries from 2427 pT3
colorectal resection specimens spanning 45 years: recommenda-
tions for a minimum number of recovered lymph nodes based on
predictive probabilities. Am J Surg Pathol 26:179–189
8. Hernanz F, Revuelta S, Redondo C, Madrazo C, Castillo J,
Gomez-Fleitas M (1994) Colorectal adenocarcinoma: quality of
the assessment of lymph node metastases. Dis Colon Rectum
37:373–376
9. Haboubi NY, Abdalla SA, Amini S, Clark P, Dougal M, Dube A,
Schofield P (1998) The novel combination of fat clearance and
immunohistochemistry improves prediction of the outcome of
patients with colorectal carcinomas: a preliminary study. Int J
Colorectal Dis 13:99–102
10. Greenson JK, Isenhart CE, Rice R, Mojzisik C, Houchens D,
Martin EW Jr (1994) Identification of occult micrometastases in
pericolic lymph nodes of Duke’s B colorectal cancer patients
using monoclonal antibodies against cytokeratin and CC49.
Correlation with long-term survival. Cancer 73:563–569
11. Liefers GJ, Cleton-Jansen AM, Velde CJ, Hermans J, Krieken JH,
Cornelisse CJ, Tollenaar RA (1998) Micrometastases and survival
in stage II colorectal cancer. N Engl J Med 339:223–228
12. Iddings D, Ahmad A, Elashoff D, Bilchik A (2006) The
prognostic effect of micrometastases in previously staged lymph
node negative (N0) colorectal carcinoma: a meta-analysis. Ann
Surg Oncol 13:1386–1392
13. Noura S, Yamamoto H, Ohnishi T, Masuda N, Matsumoto T,
Takayama O, Fukunaga H, Miyake Y, Ikenaga M, Ikeda M,
Sekimoto M, Matsuura N, Monden M (2002) Comparative
detection of lymph node micrometastases of stage II colorectal
cancer by reverse transcriptase polymerase chain reaction and
immunohistochemistry. J Clin Oncol 20:4232–4241
14. Bertagnolli M, Miedema B, Redston M, Dowell J, Niedzwiecki D,
Fleshman J, Bem J, Mayer R, Zinner M, Compton C (2004)
Sentinel node staging of resectable colon cancer: results of a
multicenter study. Ann Surg 240:624–628
15. Bilchik AJ, Saha S, Wiese D, Stonecypher JA, Wood TF,
Sostrin S, Turner RR, Wang HJ, Morton DL, Hoon DS (2001)
Molecular staging of early colon cancer on the basis of sentinel
node analysis: a multicenter phase II trial. J Clin Oncol 19:1128–
1136
16. Braat AE, Oosterhuis JW, Moll FC, Vries JE (2004) Successful
sentinel node identification in colon carcinoma using Patent Blue
V. Eur J Surg Oncol 30:633–637
17. Joosten JJ, Strobbe LJ, Wauters CA, Pruszczynski M, Wobbes T,
Ruers TJ (1999) Intraoperative lymphatic mapping and the
Int J Colorectal Dis (2007) 22:1509–1514 1513sentinel node concept in colorectal carcinoma. Br J Surg 86:482–
486
18. Saha S, Nora D, Wong JH, Weise D (2000) Sentinel lymph node
mapping in colorectal cancer—a review. Surg Clin North Am
80:1811–1819
19. Tsioulias GJ, Wood TF, Spirt M, Morton DL, Bilchik AJ (2002) A
novel lymphatic mapping technique to improve localization and
staging of early colon cancer during laparoscopic colectomy. Am
Surg 68:561–565
20. Paramo JC, Summerall J, Poppiti R, Mesko TW (2002) Validation
of sentinel node mapping in patients with colon cancer. Ann Surg
Oncol 9:550–554
21. Read TE, Fleshman JW, Caushaj PF (2005) Sentinel lymph node
mapping for adenocarcinoma of the colon does not improve
staging accuracy. Dis Colon Rectum 48:80–85
22. Bilchik AJ, Saha S, Tsioulias GJ, Wood TF, Morton DL (2001)
Aberrant drainage and missed micrometastases: the value of
lymphatic mapping and focused analysis of sentinel lymph nodes
in gastrointestinal neoplasms. Ann Surg Oncol 8:82S–85S
23. Wong JH, Severino R, Honnebier MB, Tom P, Namiki TS (1999)
Number of nodes examined and staging accuracy in colorectal
carcinoma. J Clin Oncol 17:2896–2900
24. Le Voyer TE, Sigurdson ER, Hanlon AL, Mayer RJ, MacDonald JS,
Catalano PJ, Haller DG (2003) Colon cancer survival is associated
with increasing number of lymph nodes analyzed: a secondary
survey of intergroup trial INT-0089. J Clin Oncol 21:2912–2919
25. Turner RR, Nora DT, Trocha SD, Bilchik AJ (2003) Colorectal
carcinoma nodal staging. Frequency and nature of cytokeratin-
positive cells in sentinel and nonsentinel lymph nodes. Arch
Pathol Lab Med 127:673–679
26. Bembenek A, Schneider U, Gretschel S, Fischer J, Schlag PM
(2005) Detection of lymph node micrometastases and isolated
tumor cells in sentinel and nonsentinel lymph nodes of colon
cancer patients. World J Surg 29:1172–1175
1514 Int J Colorectal Dis (2007) 22:1509–1514